Drug Profile
TH 9506
Latest Information Update: 20 Mar 2008
Price :
$50
*
At a glance
- Originator Theratechnologies
- Developer Ipsen; Theratechnologies
- Class Heart failure therapies; Peptide hormones
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 20 Feb 1997 Phase-I clinical trials for Somatotropin deficiency in Europe (Unknown route)